Overview of Pharmacotherapy for COVID-19 Management

Introduction

the current epidemic of COVID-19 requires a lot of efforts to be controlled involving pharmacotherapy and clinical pharmacology studies. Aim: to introduce a brief review of drugs under investigation for COVID-19.

Methodology

Our project is a systematic review of many medications being studied for their effectiveness and safety in COVID-19 management.

Results

Antiviral drugs (osletmivir, ramdisvir), corticosteroids (dexamethasone), immunomodulators (anakinera, toculizumab), antithrombotic (antiplatletes, anticoagulants) are still under investigation although preliminary results are promising.

Conclusion

Yet, few medications have been approved by FDA for management of COVID-19 but drugs have been used in clinical trials under FDA emergency use authorization. Ongoing clinical trials are essential to establish their long-term safety and effectiveness. Key points: 1. Scientists are testing different medicines, such as antivirals, steroids, immune-boosting drugs, and blood thinners, to see if they can help treat COVID-19. 2. Some of these drugs show early promise, but only a few have official approval for use. 3. More research and clinical trials are needed to make sure these treatments are safe and work well in the long run.